undamentalytics Newsletter
Sign in

Vyome Holdings, Inc revenue

Vyome Holdings, Inc's revenue was $319,714 in fiscal 2025, down 96.0% on the year before. Since fiscal 2014 ($3.5m) it has grown at a compound -19.6% a year. Over the last twelve months it was $129,724.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue44310931114119800
Growth on the year before—+14.1%−16.0%+192.2%−8.2%−63.9%+244.4%+20.4%−17.4%−22.8%−7.7%−96.0%—
Gross profit1215406876000
Gross margin17.7%38.0%17.2%51.3%40.4%10.1%55.4%61.4%60.5%63.9%2.4%68.4%52.7%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $174,645 54.6% ▲ 29.9%
Licenses $116,900 36.6% —
Royalty $28,169 8.8% ▼ 40.6%

From Vyome Holdings, Inc's 10-K filed March 18, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Vyome Holdings, Inc $129,724 -98.0% -76.8%
Akanda Corp. $258,075 -69.2% —
Scienture Holdings, Inc. $821,315 540.6% -58.5%
PRF Technologies Ltd. $17,000 — —
60 Degrees Pharmaceuticals, Inc. $1.1m 73.2% 74.9%
China SXT Pharmaceuticals, Inc. $1.1m -34.6% —

Compare with peers

Head to head: AKAN vs HINDHIND vs SCNXHIND vs PRFX

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Vyome Holdings, Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Vyome Holdings, Inc.